AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03325803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study NCT02100033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT04074707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Labeled iron solution (60mg and 120mg Ferrous Fumarate)
Description: 3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
Study NCT00125385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
Study NCT00125385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
Study NCT00125385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
Study NCT00125385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
Study NCT00125385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
Study NCT03955185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgery
Description: Laparoscopic or robotic assisted radical hysterectomy
Study NCT03955185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open abdominal surgery
Description: Traditional open abdominal radical hysterectomy
Study NCT05554224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: To propose diagnostic tests for liver diseases before surgical decisions.
Description: Observational although patients are candidates for metabolic surgery.
Study NCT04204252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha 1-Antitrypsin
Description: Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
Study NCT04204252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
Study NCT05309746 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
Study NCT00247390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
Study NCT00247390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
Study NCT02163408 — intervention group
Intervention type: OTHER
Intervention: MRI with/without contrast
Description: Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
Study NCT02453412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVF-simulation
Description: A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
Study NCT02961764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
Study NCT02961764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin
Description: Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
Study NCT01430221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Personalized Health Planning
Study NCT01430221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured & Guided Education
Study NCT03333369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg levodopa/50 mg benserazide
Study NCT03333369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Study NCT02242539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Height measurement poster
Description: Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
Study NCT02242539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based monitoring
Description: Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day.
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.
Study NCT03760068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYL-1601D Product
Description: (100 U/mL)
Study NCT03760068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FlexPen NovoLog®
Description: (100 U/mL)
Study NCT04044287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 micrograms of misoprostol
Description: 200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
Study NCT04044287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
Study NCT02831036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training program
Description: subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
Study NCT02831036 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VO2max test
Description: each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
Study NCT02831036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VO2max test
Description: each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
Study NCT02831036 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: spatial orientation test
Description: each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
Study NCT02831036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spatial orientation test
Description: each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
Study NCT01871727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777 9 mcg/kg
Description: administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
Study NCT00469014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Infusion
Description: Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
Study NCT01622127 — intervention group
Intervention type: DEVICE
Intervention: Parietex ProGrip™
Description: ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
Study NCT00599781 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene transduced PBL and/or gene transduced HSC
Description: infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
Study NCT00475475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
Study NCT00475475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: glucose
Description: 25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
Study NCT00475475 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: non-caloric sweetener
Description: 25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
Study NCT04008043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicodin
Description: In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Study NCT04008043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Study NCT03251677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedure, Hysterectomy
Description: Surgical removal of the uterus
Study NCT01070797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-virus Specific T cells
Description: Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days.
Study NCT02515812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I-123-MIBG
Study NCT02515812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123-MIBG
Study NCT02515812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CZT Camera (D-SPECT)
Study NCT02515812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anger Camera
Study NCT02519387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Patch
Study NCT04251156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
Study NCT04251156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Study NCT03570138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System
Description: Specific therapeutic education for diabetes self management
Study NCT03570138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual self monitoring Blood Glucose device
Description: Standard therapeutic education for diabetes self management
Study NCT02970188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: consuming all daily calories within an 8 hour feeding window
Study NCT02573662 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood and Urine sampling
Description: Blood and Urine Sampling
Study NCT00469014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
Study NCT02573662 — intervention group
Intervention type: RADIATION
Intervention: DXA scan
Description: Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin (ATG)
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study NCT02573662 — intervention group
Intervention type: BIOLOGICAL
Intervention: OGTT
Description: Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
Study NCT05104996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
Study NCT03577561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proficiency Based Progression Training in Phlebotomy
Description: Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
Study NCT01129258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
Study NCT00469014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study NCT01129258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
Study NCT03616379 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational Control
Description: The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
Study NCT00736736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Hip Muscle Strengthening to Leg Press Exercise
Study NCT00736736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leg Press Exercise
Study NCT01905267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused Cognitive Behavior Therapy
Description: This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
Study NCT03616379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation
Description: In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
Study NCT03616379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Labelling
Description: In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
Study NCT00730600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thai Traditional massage
Description: Thai traditional massage for 2 hours by a single masseuse.